Prof. Solomon gives a comprehensive overview of the PARAGON-HF trial and present results of an analysis of combined data of the PARADIGM-HF and PARAGON-HF trials. With question to test your knowledge.
Sacubitril-valsartan was well tolerated in stable HFrEF patients in a real-world population. Target dose was achieved in most patients and was linked to down-titration of diuretic dose.
Three phenogroups were identified in TOPCAT HFpEF patients, ranging from a low-risk group with mild symptoms to a high-risk obese, diabetic group with advanced symptoms that responded well to spironolactone.
This pilot RCT in acute decompensated HF patients showed that empagliflozin did not result in reduction of primary endpoints, but did reduce a combined endpoint of worsening HF, rehospitalization for HF or death compared to placebo.
The EVALUATE-HF trial was set up to study the effects of sacubitril/valsartan treatment on cardiac and hemodynamic mechanisms, to look into how these may explain the observed clinical benefits.
This prospective registry study of a real-world cohort of elderly HFrEF patients showed that sacubitril/valsartan was safe and effective, even in those >80 years.
Prof. Pieske gives a broad overview of heart failure with mid range ejection fraction, including prevalence, etiolgies and treatment options.
Results of the EMPERIAL-Reduced and EMPERIAL-Preserved trials were announced, which both showed no benefit in exercise ability with use of empagliflozin in HFrEF and HFpEF patients, respectively.
A subanalysis of the PIONEER-HF trial was performed to examine whether sacubitril/valsartan was effective and safe in high-risk subgroups. Prof Morrow gives a brief presentation of this analysis.
This video series addresses the effect of SGLT2i on kidney outcomes in diabetes patients with chronic kidney disease (CKD). Member registration (free) is needed to enroll in this course.
Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.
PARAGON-HF data suggest that patients with HFpEF with a recent hospitalization have higher rehospitalization rates than those with more distant or no hospitalization, and they may respond better to sacubitril/valsartan.